Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Mirtazapine
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Approved FDF
Recipient : Kindred Biosciences
Deal Size : $43.0 million
Deal Type : Divestment
Kindred Biosciences Announces Mirataz® (mirtazapine transdermal ointment) Transaction
Details : The company has entered into a transaction for the sale of Mirataz® to Dechra Pharmaceuticals PLC.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $43.0 million
March 16, 2020
Lead Product(s) : Mirtazapine
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Approved FDF
Recipient : Kindred Biosciences
Deal Size : $43.0 million
Deal Type : Divestment
Reset All
